BSE:532660

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals in India, Mexico, Spain, Hungary, and internationally. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has Vivimed Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 532660's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

532660

-1.0%

IN Pharmaceuticals

-0.4%

IN Market


1 Year Return

17.0%

532660

50.1%

IN Pharmaceuticals

2.3%

IN Market

Return vs Industry: 532660 underperformed the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: 532660 exceeded the Indian Market which returned 2% over the past year.


Shareholder returns

532660IndustryMarket
7 Day-3.1%-1.0%-0.4%
30 Day-20.4%-0.3%3.3%
90 Day29.3%12.8%6.7%
1 Year17.0%17.0%52.1%50.1%4.0%2.3%
3 Year-87.2%-87.3%29.8%26.3%0.6%-4.1%
5 Year-78.5%-78.7%0.5%-3.1%42.3%31.8%

Price Volatility Vs. Market

How volatile is Vivimed Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vivimed Labs undervalued compared to its fair value and its price relative to the market?

0.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 532660's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 532660's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 532660 is unprofitable, so we can't compare its PE Ratio to the IN Pharmaceuticals industry average.

PE vs Market: 532660 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 532660's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 532660 is good value based on its PB Ratio (0.3x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Vivimed Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vivimed Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vivimed Labs performed over the past 5 years?

-34.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 532660 is currently unprofitable.

Growing Profit Margin: 532660 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 532660 is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.

Accelerating Growth: Unable to compare 532660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 532660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).


Return on Equity

High ROE: 532660 has a negative Return on Equity (-12.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vivimed Labs's financial position?


Financial Position Analysis

Short Term Liabilities: 532660's short term assets (₹9.8B) exceed its short term liabilities (₹7.7B).

Long Term Liabilities: 532660's short term assets (₹9.8B) exceed its long term liabilities (₹6.0B).


Debt to Equity History and Analysis

Debt Level: 532660's debt to equity ratio (116%) is considered high.

Reducing Debt: 532660's debt to equity ratio has reduced from 156% to 116% over the past 5 years.

Debt Coverage: 532660's debt is not well covered by operating cash flow (8.2%).

Interest Coverage: Insufficient data to determine if 532660's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Vivimed Labs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 532660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 532660's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 532660's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 532660's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 532660 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 532660's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Ramesh Krishnamurthy

0.33

Tenure

Mr. Ramesh Krishnamurthy has been Chief Executive Officer at Vivimed Labs Limited since June 1, 2020. He serves as Managing Director of Basil UK Limited of Basil Communications Private Limited. He is Chief ...


Leadership Team

NamePositionTenureCompensationOwnership
Yugandhar Kopparthi
Compliance Officer & Company Secretaryno data₹2.29mno data
Santosh Varalwar
MD & Executive Director30.92yrs₹6.00m6.75%
₹ 88.5m
Manohar Varalwar
Whole Time Director25.92yrs₹6.00m1.56%
₹ 20.4m
Sandeep Varalwar
Executive Director12.75yrs₹6.00m2.26%
₹ 29.6m
Ramesh Krishnamurthy
Chief Executive Officer0.33yrno datano data
Mark Robbins
Chief Executive of Uquifa - Vivimed’s API Division30.75yrsno datano data
Snehashree Joshi
Assistant Company Secretaryno datano datano data
Amarjit Bhatia
Advisor of Vivimed Group4.5yrs₹4.38mno data

1.6yrs

Average Tenure

57yo

Average Age

Experienced Management: 532660's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Santosh Varalwar
MD & Executive Director30.92yrs₹6.00m6.75%
₹ 88.5m
Manohar Varalwar
Whole Time Director25.92yrs₹6.00m1.56%
₹ 20.4m
Sandeep Varalwar
Executive Director12.75yrs₹6.00m2.26%
₹ 29.6m
Subhash Varalwar
Non-Executive Promoter Director30.92yrs₹225.00k1.95%
₹ 25.5m
Mamidpalli Rao
Independent Non-Executive Chairmanno data₹425.00kno data
Umanath Varahabhotla
Independent Non-Executive Director5.58yrs₹375.00kno data
Jamalapuram Harigopal
Independent Director0.42yrno datano data

19.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 532660's board of directors are seasoned and experienced ( 19.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vivimed Labs Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vivimed Labs Limited
  • Ticker: 532660
  • Exchange: BSE
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.310b
  • Shares outstanding: 82.91m
  • Website: https://www.vivimedlabs.com

Number of Employees


Location

  • Vivimed Labs Limited
  • North End
  • Road No.2
  • Hyderabad
  • Andhra Pradesh
  • 500034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532660BSE (Mumbai Stock Exchange)YesEquity SharesININRAug 2005
VIVIMEDLABNSEI (National Stock Exchange of India)YesEquity SharesININRAug 2005

Biography

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals in India, Mexico, Spain, Hungary ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 12:45
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.